{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:43:25Z","timestamp":1793659405839,"version":"4.5.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.humpath.2020.07.022","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T20:16:05Z","timestamp":1596485765000},"page":"54-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Concordance of breast cancer biomarker status between routine immunohistochemistry\/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0079-4459","authenticated-orcid":false,"given":"Haley","family":"Sechrist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0970-7697","authenticated-orcid":false,"given":"Akisha","family":"Glasgow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bomeisl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Gilmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Harbhajanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2020.07.022_bib1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/me.2016-1072","article-title":"Minireview: the link between ER\u03b1 corepressors and histone deacetylases in tamoxifen resistance in breast cancer","volume":"30","author":"L\u00e9gar\u00e9","year":"2016","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.humpath.2020.07.022_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/PAI.0b013e3181cddde9","article-title":"Concordance between semiquantitative immunohistochemical assay and Oncotype DX RT-PCR assay for estrogen and progesterone receptors","volume":"18","author":"O'Connor","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2020.07.022_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","article-title":"Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer","volume":"161","author":"Li","year":"2017","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.humpath.2020.07.022_bib4","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1200\/JCO.2007.15.8659","article-title":"Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2020.07.022_bib5","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1200\/JCO.2007.11.9453","article-title":"Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98","volume":"25","author":"Viale","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2020.07.022_bib6","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2003.09.099","article-title":"Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases","volume":"21","author":"Bardou","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2020.07.022_bib7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2020.07.022_bib8","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2020.07.022_bib9","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor\u2013positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2020.07.022_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2020.07.022_bib11","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Sparano","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2020.07.022_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.hemonc.2015.12.001","article-title":"Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score","volume":"9","author":"Sparano","year":"2016","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.humpath.2020.07.022_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-018-4955-z","article-title":"Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma","volume":"172","author":"Huang","year":"2018","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.humpath.2020.07.022_bib14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/annonc\/mdl016","article-title":"Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status","volume":"17","author":"Dowsett","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2020.07.022_bib15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2020.07.022_bib16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/modpathol.2011.194","article-title":"A mitotically active, cellular tumor stroma and\/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas","volume":"25","author":"Acs","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2020.07.022_bib17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/PAI.0b013e3182632ff5","article-title":"Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the Oncotype DX test","volume":"21","author":"Dvorak","year":"2013","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2020.07.022_bib18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/tbj.13110","article-title":"Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases","volume":"24","author":"Neely","year":"2018","journal-title":"Breast J"},{"key":"10.1016\/j.humpath.2020.07.022_bib19","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/modpathol.2011.219","article-title":"Semi-quantitative immunohistochemical assay versus oncotype DX qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study","volume":"25","author":"Kraus","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2020.07.022_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/tbj.12223","article-title":"ER and PR Immunohistochemistry and HER2 FISH versus Oncotype DX: implications for breast cancer treatment","volume":"20","author":"Park","year":"2014","journal-title":"Breast J"},{"key":"10.1016\/j.humpath.2020.07.022_bib21","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2007.13.6424","article-title":"Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory","volume":"26","author":"Badve","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2020.07.022_bib22","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1200\/JCO.2011.34.7963","article-title":"High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study","volume":"29","author":"Dabbs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2020.07.022_bib23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1309\/AJCPSKFWOLPPMEU9","article-title":"A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results","volume":"132","author":"Brock","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2020.07.022_bib24","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1200\/JCO.2005.05.4155","article-title":"Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival","volume":"24","author":"Cheang","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2020.07.022_bib25","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American society of clinical oncology\/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2020.07.022_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2020.07.022_bib27","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer","volume":"17","author":"Harvey","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2020.07.022_bib28","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/modpathol.3800229","article-title":"Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study","volume":"17","author":"Mohsin","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2020.07.022_bib29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2007.12.9437","article-title":"Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial","volume":"26","author":"Dowsett","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817720301465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817720301465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:37:27Z","timestamp":1758645447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817720301465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":29,"alternative-id":["S0046817720301465"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2020.07.022","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concordance of breast cancer biomarker status between routine immunohistochemistry\/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2020.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}